Eiger BioPharmaceuticals, Inc. (EIGR) saw its loss widen to $11.24 million, or $1.34 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $9.75 million, or $10.42 a share.
The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $10.99 million, compared with an operating loss of $8.68 million in the previous year period.
"Building on our achievements in 2016, we have continued to execute on all programs in 2017, and are we anticipating multiple key clinical and regulatory milestones in later in 2017 and 2018," said David Cory, president and chief executive officer of Eiger BioPharmaceuticals.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
